InspireMD Inc. (NASDAQ: NSPR) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT INSPIREMD INC.

InspireMD Inc. (NASDAQ: NSPR)
Listen to this Section


$0.89
-0.0400 ( -4.32% ) 89.1K

InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.

Market Data


Open $0.89
Previous Close $0.93
Volume 89.1K
Market Cap $44.97M
Day Range $0.83 - $0.97
52 Week Range $0.83 - $2.93
Shares Outstanding 46.84M
Change % -4.32%
Net Change ▼ -0.0400
Insider Ownership -0.15%
Exchange NASDAQ
SectorHealthcare
IndustryMedical/Dental Instruments
IPO Year1997
CountryIsrael

Insider Ownership Transactions

Total Amount Purchased: -1,608,915.00

Date Type Amount Purchased Purchaser
2024-01-25 Sale -29032.00 Kester Thomas J
2024-01-25 Sale -238625.00 Gleason Shane Thomas
2024-01-25 Sale -43548.00 Stuka Paul
2024-01-25 Sale -85720.00 Verta Patrick
2024-01-25 Sale -29032.00 BERMAN MICHAEL
2024-01-25 Sale -563499.00 Slosman Marvin
2024-01-25 Sale -29032.00 Arnold Kathryn
2024-01-25 Sale -29032.00 ROUBIN GARY S
2024-01-25 Sale -238625.00 Shore Craig
2024-01-11 Sale -3183.00 Kester Thomas J

SEC Filings


Form Type Description Pages Date
schedule Other 1 Nov 14, 2025
schedule Other 2 Nov 14, 2025
schedule Other 1 Nov 14, 2025
schedule Other 1 Nov 14, 2025
schedule Other 1 Nov 14, 2025
4 Insider transactions 2 Nov 13, 2025
10-q Quarterly Reports 64 Nov 10, 2025
8-k 8K-related 47 Nov 04, 2025
4 Insider transactions 2 Oct 09, 2025
3 Insider transactions 1 Sep 24, 2025

Latest News


× Before browsing our site, please accept our cookies policy